Drug intelligence / Profile preview

DKF-306

Development stage: Phase 4
Lead developer: Dongkook Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DKF-306 is an investigational drug being evaluated for the treatment of periodontal diseases. It is currently undergoing a multi-center, randomized, double-blinded, placebo-controlled Phase 4 clinical trial to assess its efficacy and safety in patients with periodontal conditions. The study involves oral administration of the drug in tablet form over a 12-week period. The primary outcome measure is the change in gingival index from baseline to week 12, with secondary outcomes including changes in bleeding on probing, plaque index, probing pocket depth, and clinical attachment level. The developer and sponsor of this drug is Dongkook Pharmaceutical.

Brand names: DKF-306DKF306DKF 306
Other names: DKF-306DKF306DKF 306

Beyond the preview

Go deeper on DKF-306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DKF-306.

Explore the full profile